Allergan Results Boosted by New, Established Drugs -- Update
February 08 2017 - 11:39AM
Dow Jones News
By Austen Hufford
Allergan PLC said revenue rose as results were bolstered by both
new and established drugs.
Shares rose 1.8% in early trading as the company also reported a
higher-than-expected revenue outlook.
For the year, Allergan said it expects adjusted revenue of $15.5
billion to $15.8 billion and adjusted earnings of $15.80 to $16.30
a share. Analysts had expected revenue of $15.37 billion and
earnings per share of $16.01.
Last year Allergan and Pfizer Inc. terminated a planned $150
billion merger after the Obama administration took aim at the deal
and Allergan also completed the sale of its generics business to
Teva Pharmaceutical Industries Ltd. Allergan said in November that
it would return more cash to shareholders because the drugmaker
isn't interested in a making a megadeal.
"Clearly having those two big transactions to deal with in 2016
did take some of our time," Chief Executive Brent Saunders said.
"I'm looking forward to 2017, where we can really focus on
execution."
During the quarter, new drug launches accounted for $90 million
in revenue. Vraylar, a drug to treat bipolar and schizophrenia, had
$43.2 million in revenue in the quarter and was taken by about
40,000 patients during its first year.
For the fourth quarter, Allergan reported a loss of $0.6
million, or 20 cents a share, compared with a loss of $630.9
million, or $1.78 a share, a year prior. Much of the decreased loss
came from an income tax benefit.
Excluding special charges and items related to acquisitions and
divestitures, earnings were $3.90 a share. Revenue rose 7.1% to
$3.86 billion.
Analysts had projected adjusted earnings of $3.76 a share on
revenue of $3.77 billion, according to Thomson Reuters.
Several drugs across Allergan's portfolio logged double-digit
sales increases, with revenue from antiwrinkle treatment Botox
increasing 14% to $739.3 million and sales of transplant drug
Restasis sales rising 13% to $411.4 million. Irritable bowel
syndrome treatment Linzess, which is known as Constella outside the
U.S., had sales of $178.2 million, up 36%.
Sales in its U.S. general medicine segment fell 0.1% to $1.53
billion, on a decline in central nervous system drugs. U.S.
specialized therapeutics revenue grew 11% to $1.57 billion on
growth in eye care, facial aesthetics, neuroscience and urology.
International sales grew 9% to $953.2 million on eye care and
facial aesthetics.
Write to Austen Hufford at austen.hufford@wsj.com
(END) Dow Jones Newswires
February 08, 2017 11:24 ET (16:24 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024